A Novel Microparticle-Based Vaccine for Delivery of Leptospiral Antigens in Animals

Versatile vaccine platform.First-in class microparticle formulation.Novel formulation is easier to produce than current formulations.
  • Versatile vaccine platform.
  • First-in class microparticle formulation.
  • Novel formulation is easier to produce than current formulations.


Technology Description

Leptospirosis is a bacterial infectious caused by the bacteria Leptospira interrogans. Humans are often infected through interactions with livestock, and symptoms can range from mild and flu-like to life-threatening. In livestock, particularly dairy and beef cattle, reproductive failure (infertility and abortion) and poor milk yield due to Leptospira infection are major problems. Disease prevention has become a high priority to avoid high rates of disease in the herd and to also break the transmission cycle to humans. Thus, there remains an important unmet need for a prophylactic vaccine that can provide long-term immunity against leptospirosis in cattle.

Inventors at the University of Iowa have developed a prophylactic vaccine for livestock to prevent the transmission of infection and break the infection transmission cycle between animals and humans. The vaccine formulation was developed using poly(diaminosulfide) polymer fabricated microparticles encapsulating the antigen of Leptospira borgpetersenii serovar Hardjo strain HB15B203 (L203-PNSN). Vaccination in cattle enhanced Leptospira-specific immune responses as evidenced by the increase in the L203-specific immune cell population and L203-specific antibody serum titers. Thus, L203-PNSN is a novel first-in-class microparticle-based Leptospira vaccine that represents a powerful platform with the potential to serve as a prophylactic vaccine against leptospiral infection in cattle.

UIRF Case No. 2019-082

Stage of Development

The L203-PNSN vaccine has been developed and tested in cattle using a prime-boost regimen with a 4-week interval.




Increases the population of L203-specific CD3+ T cells and CD21+ B cells

Less batch-to-batch variation than current Leptospirosis vaccines

Versatile vaccine platform: can be refined to enhance efficacy against several serovars

The formulation is easier to produce and store than current whole-cell vaccines

Contact Information:

Name : Mihaela D. Bojin

Title :

Department :

Email: mihaela-bojin@uiowa.edu

Phone: 319-335-2723

Address :